Dr. Lawrence Corey

Lawrence Corey, M.D.
Co-Principal Investigator, HVTN Leadership and Operations Center

Dr. Corey is past president and director of the Fred Hutchinson Cancer Research Center and a professor of its Vaccine and Infectious Disease, Public Health Sciences and Clinical Research divisions. He is a professor of medicine and laboratory medicine at the University of Washington, was head of the Virology Division at the University of Washington from 1978 to 2010, and led the AIDS Clinical Trials Group (ACTG) from 1987 to 1992. He has been Principal Investigator of the HVTN since its inception in 1999.

An internationally renowned expert in virology, viral immunology and vaccine development, Corey’s research has transformed the way we manage patients globally. With Nobel Laureate Dr. Gertrude Elion, he was the first to demonstrate that an antiviral compound, acyclovir, specific for a viral enzyme could be safely and effectively administered to control a chronic viral infection. These studies provided the foundation for the subsequent development of antiviral therapy for HIV and hepatitis viruses. Under his leadership at the ACTG, AZT was shown to reduce maternal fetal transmission; providing the impetus for the introduction of antiretrovirals to avert pediatric HIV infections internationally. He pioneered the use of viral load as predictors of clinical benefit and his studies demonstrating the early administration of combination antiretroviral therapy provided the strategy to reduce HIV morbidity and mortality globally. Corey’s work in HSV-2 established the framework for understanding the herpes pandemic and its role in HIV acquisition and progression.

Corey received his B.S. and M.D. from the University of Michigan and his infectious diseases training at the University of Washington. He is a member of the US National Academy of Medicine and the American Academy of Arts and Sciences, was the recipient of the Parran Award for his work in HSV-2, the American Society of Microbiology Cubist Award for his work on antivirals, and the University of Michigan Medical School Distinguished Alumnus Award. He is one of the most highly cited biomedical researchers in the last 20 years and is the author, coauthor or editor of over 1000 scientific publications.

Dr. Glenda Gray

Glenda Gray, M.B.B.C.H., F.C.Paed (SA)
Co-Principal Investigator, HVTN Leadership and Operations Center

Dr. Gray is the President & CEO of the South African Medical Research Council . She is a Research Professor of Paediatrics at the University of the Witwatersrand, and a director at the Perinatal HIV Research Unit in Soweto. Trained as a paediatrician, she was awarded a Fogarty Training Fellowship at Columbia University in 1999 and also completed an intensive program on clinical epidemiology at Cornell University. Based in South Africa, she is the Co-PI of the HVTN and Director of HVTN Africa Programs. She is a member of the Vaccine and Infectious Disease Division at the Fred Hutch. She has expertise in the field of mother to child transmission of HIV, adolescent HIV prevention and treatment, and HIV vaccine and microbicide research.

She received the Femina "Woman of the Nineties" Award, for her contribution to Perinatal HIV Research. In 2002, together with James McIntyre, she was awarded the Nelson Mandela Health and Human Rights Award for pioneering work done in the field of Mother-to-Child Transmission of HIV-1. Glenda was awarded the IAPAC "Hero of Medicine" award for work done in the field of HIV treatment in children and adults. In 2009, together with James McIntyre she received the N'Galy-Mann lectureship at CROI in recognition of their HIV research contribution in South Africa. She is a member of the Academy of Science in South Africa, Chair of their Standing Committee on Health and has served on a number of expert panels for the Academy in the field of infant health, nutrition and HIV. She was elected as a foreign associate into the US Institute of Medicine of the National Academy of Sciences and serves on their Board of Global Health. She is also a Fellow of the American Academy of Microbiology. She serves on IAVI’s Scientific Advisory Committee, and is a member of the Scripps CHAVI-ID Scientific Advisory Board. In 2013, she received the Order of Mapungubwe, South Africa’s highest honor, for achievements in the international arena which have served South Africa's interests. In the same year she received the EDCTP Outstanding African Scientist award.

Glenda became involved in HIV Vaccine research in 2000, and led the first clinical trials involving HIV vaccines in the Republic of South Africa (RSA). She was the Protocol Chair for the first phase 2B HIV vaccine trial to be conducted in sub-Saharan Africa, and was in charge of the early clinical development of South Africa's first two candidate DNA and MVA HIV vaccines, which have been tested in both the USA and RSA under FDA and MCC regulations. She was the International Vice Chair for Vaccines for the NIH-funded IMPAACT network until 2010. She has published extensively in the field of HIV. 

Dr. Troy Martin

Troy Martin, M.D., M.P.H.
Chief of Staff, HVTN Leadership and Operations Center

Dr. Martin is the Chief of Staff of the HIV Vaccine Trials Network based at Fred Hutchinson Cancer Research Center.

He is an infectious diseases and internal medicine physician and former Assistant Professor of Medicine at Brown University.  He has experience conducting clinical trials in HIV, malaria, smallpox and other infectious diseases and performing molecular research in the neurosciences and HIV.  He has led program operations in academic, community, and international settings with extensive experience in Asia and Africa. He has served as a trainer and on-site mentor for HIV/AIDS, tuberculosis care for children and adults and has provided clinical supervision and laboratory support for national malaria and HIV treatment programs. Dr. Martin has 15+ years of experience managing multidisciplinary teams and developing effective working relationships with government officials, international non-governmental organizations (NGOs), hospital administrators, and clinicians. He supported the development of national systems for drug procurement, laboratory networks, and treatment facilities.  Dr. Martin completed his B.S. in biochemistry at Washington State University, his M.D. at the University of Washington and an M.P.H from Harvard University.  His residency and fellowship training were at Brown University.

Dr. Martin works on many aspects of improving our operational and scientific productivity with our clinical trial sites, and alliance management with our network and NIAID partners.

Dr. Susan Buchbinder

Susan Buchbinder, M.D.
Site Principal Investigator Representative

Dr. Buchbinder is the director of Bridge HIV at the San Francisco Department of Public Health (SFDPH) and Clinical Professor of Medicine, Epidemiology and Biostatistics at the University of California, San Francisco (UCSF). Her research focuses on risk factors for HIV acquisition and interventions to prevent HIV infection, including HIV vaccines, pre-exposure prophylaxis, behavioral interventions, microbicides and combination modalities.

She has served in leadership positions in the HIV Vaccine Trials Network and HIV Prevention Trials Network, and has participated in numerous NIH and UCSF advisory committees including the AIDS Research Advisory Committee, Prevention Sciences Working Group, Office of AIDS Research Advisory Committee, UCSF Center for AIDS Research Internal Advisory Board, UCSF AIDS Research Institute Scientific Council. Dr. Buchbinder has over 240 publications in peer-reviewed journals.

Dr. Peter Gilbert

Peter Gilbert, Ph.D.
Principal Investigator, Statistical Data and Management Center

Dr. Gilbert is Principal Investigator of the Statistical Data Management Center for the HIV Vaccine Trials Network and the Head of the Biostatistics, Bioinformatics, and Epidemiology Program within the Vaccine and Infectious Disease Division of the Fred Hutchinson Cancer Research Center. He is also a Member of the Public Health Sciences Division and is a Research Professor in the Department of Biostatistics at the University of Washington. Gilbert is an active mentor to a number of graduate and post-graduate students from the University of Washington and enjoys accomplishing research objectives with their collaboration.

His current research interests center on the statistical design and analysis of vaccine efficacy trials, with emphasis on assessing immune correlates of vaccine-induced protection including the "sieve analysis" of the pathogen sequences infecting trial volunteers. While being motivated by vaccine efficacy trials for HIV and other pathogens, this research contributes to general areas of statistical methods research including surrogate endpoint assessment, causal inference, survival analysis, and efficient randomized trial design. In collaboration with scientists from the Thai Ministry of Health and the United States Military HIV Research Program, he led the statistical design and analysis of an immune correlates study of the RV144 "Thai Trial" (published in 2012), which established a process for correlates discovery that may be useful for other vaccine trial settings. In addition, Peter led the statistical design of a sequential Phase 2b trial design for evaluating vaccine efficacy and immune correlates for multiple HIV vaccine regimens (published in 2011), which is planned for implementation and may be useful for other vaccine trial settings.

Gilbert holds a B.S. in Mathematics (1992) as well as an M.S. and Ph.D. in Biostatistics (1994 and 1996), all from the University of Washington. He was a post-doctoral fellow and Assistant Professor in the Department of Biostatistics at the Harvard School of Public Health from 1997 to 2011. Peter is a Fellow of the American Statistical Association and his service includes membership on the U.S. FDA’s advisory committee for vaccines and on Data and Safety Monitoring Boards.

Dr. yunda Huang

Yunda Huang, Ph.D
Co-Principal Investigator, Statistical Data and Management Center

Dr.  Huang’s research areas focus on the statistical design and analysis of vaccine clinical trials, monoclonal antibody clinical trials, and immunological biomarker studies related to the prevention and treatment of HIV and other infectious diseases. In the past 14+ years, she has provided statistical leadership on more than 15 phase 1/2 pre-efficacy and phase 2b efficacy trials, and on several immune correlates studies related to the Ad5-based HIV preventive Step trial, the ALVAX/AIDSVAX HIV preventive RV144 trial, and the peptide-based HIV therapeutic Vacc-4x study. In recent years, she spearheaded fruitful collaborations in bridging the gap between statistical methodology and pharmacometric applications in the design and analysis of single and combination HIV monoclonal antibody trials. 

Huang is also passionate about mentoring and supporting international students and scholars. She has served in the Hutch International Ambassador Program for 10+ years, and in the Fred Hutch undergraduate summer internship program for 3 years. She has also mentored several minority high school summer interns and co-taught 2 Statistics workshops in Brazil and South Africa. 

Dr, Holly Janes

Holly Janes, Ph.D.
Co-Principal Investigator, Statistical Data and Management Center

Dr. Janes is a biostatistician working on the design and analysis of vaccine studies, with a particular expertise in HIV prevention and vaccine science. She also develops and applies statistical methodology for evaluating biomarkers for risk prediction and optimizing treatment decisions.

Dr. James Kublin

James Kublin, M.D., M.P.H.
Executive Director

Dr. Kublin is the Executive Director of the HIV Vaccine Trials Network based at Fred Hutchinson Cancer Research Center. He is also the Medical Director of the Malaria Clinical Trials Center at Seattle BioMed, and a faculty member in the Department of Global Health at the University of Washington.

He has conducted extensive research on HIV and malaria in South America, SE Asia, and Africa, including clinical trials of novel therapies and vaccines.

Before moving to Seattle, Kublin was Director, HIV Vaccines – Infectious Diseases, for Merck & Co., Inc., where he played a key role in the development and implementation of HIV vaccine studies, overseeing the coordination of clinical assays, site identification and development, government and ethical approvals and providing guidance on vaccine policy issues.

He completed his B.S. and M.D. at Georgetown University, and received his M.P.H. and completed a residency in Preventive Medicine at Johns Hopkins University. Jim continued work in vaccine development and molecular epidemiology while attending the University of Maryland’s School of Medicine for his fellowship in Vaccinology at the Center for Vaccine Development. 

Dr. Julie McElrath

Julie McElrath, M.D., Ph.D.
Principal Investigator, HVTN Laboratory Center

Dr. McElrath is Principal Investigator and Director of the HVTN Laboratory Center and the Seattle-Lausanne Clinical Trials Unit. She is a Senior Vice President and Member of the Fred Hutchinson Cancer Research Center; Professor, Departments of Medicine, Laboratory Medicine and Global Health, University of Washington; Director of the FHCRC Vaccine and Infectious Disease Division, and directs their Immunology and Vaccine Development Program.She also has attending responsibilities on the Fred Hutchinson Cancer Research Center Infectious Diseases consult service.

McElrath's current research pursues a vaccine that will protect against HIV-1 infection, as well as investigating:

  • how components of T-cell immunity elicited early in HIV-1 infection contribute to control of HIV-1 disease,
  • what the influence of antiretroviral therapy is,
  • whether T-cell immune responses are involved in resistance to HIV-1 infection in persons at high-risk for HIV infection,
  • how antigen-specific mucosal T-cells protect against HIV-1 exposure,
  • what effect different adjuvants have on the quality and profile of the immune response to vaccination, and
  • what elements of immunity correlate with protection against HIV-1 infection by a preventive HIV vaccine.

Among her many accomplishments, Dr. McElrath has built and maintains a successful international HIV vaccine laboratory program, conducts translational immunological research in humans in a multicenter setting, contributes to the fundamental understanding of how HIV-1 enters the mucosa to establish infection, identifies persons with very low levels of HIV DNA who otherwise lack all evidence of infection, assembles invaluable cohorts from which to elucidate mechanisms of risk for HIV infection and disease, and productively mentors junior faculty, young investigators, and graduate students in their career paths. In conjunction with a highly productive research program, she has assumed a leadership role or been a major contributor in a number of integrated programs at the national and international levels to advance a coordinated effort to tackle the HIV epidemic through a range of prevention efforts: the HIV Vaccine Trials Network (PI and Director of the Laboratory Center), the Gates Foundation Collaboration for AIDS Vaccine Discovery (PI and contributor to multiple groups), the Mucosal Immunology Group (PI), the Microbicide Trials Network (Director, Immunology Core), and the Global HIV Vaccine Enterprise (Laboratory Working Group).

Dr. McElrath received her bachelor's degree from Furman University, Greenville, SC; her Ph.D. and M.D. degrees from the Medical University of South Carolina, Charleston; her clinical training in infectious diseases at Columbia Presbyterian Medical Center, New York; and her post-doctoral training in molecular immunology at Rockefeller University in New York.

Dr. Georgia Tomaras

Georgia Tomaras, Ph.D.
Co-Principal Investigator, HVTN Leadership and Operations Center

Dr. Tomaras is a tenured Professor of Surgery, Immunology and Molecular Genetics and Microbiology at Duke University. She is Director of Research for the Duke Human Vaccine Institute (DHVI), Director of the DHVI Training and Mentoring Program (and NIH T32 Co-PI), and Associate Director for the HIV Vaccine Trial Network Laboratory Center. Dr. Tomaras has over 215 peer-reviewed publications on immune correlates and interrogation of humoral and cellular immunity. She is the principal investigator of a multi-institution program project grant to decipher immune correlates of protection. Dr. Tomaras is Chair of the National Institutes of Health (NIH) AIDS Vaccine Research Subcommittee (AVRS) and served as an NIAID Advisory Council member. She serves on several scientific advisory boards for national and international consortia, is the PI and Co-Chair for the 2018 Research for Prevention (R4P) meeting in Spain and co-organizer for the Keystone Vaccine meeting 2020. She is an editorial board member for the Journal of Virology, consulting editor for the Journal of Clinical Investigation and guest editor for PLOS Pathogens. Her awards include the NIH HIV Vaccine Trials Network Mentoring Award, Norman Letvin Faculty Award and the Ruth and A. Morris Williams Faculty Research Prize, recognition as a highly cited scientist in 2017 and presented a 2017 Distinguished Graduate School Alumna lecture. Dr. Tomaras received her B.S. in biology from the University of Michigan, Ann Arbor and her Ph.D. in Microbiology and Immunology from SUNY Upstate Medical University, Syracuse, and completed her postdoctoral fellowship at Duke University. In 2018, she was elected a fellow of the American Academy o

Dr. Dan Barouch

Dan H. Barouch, M.D., Ph.D.
Co-Principal Investigator, HVTN Leadership and Operations Center

Dr. Barouch is Director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center and Professor of Medicine at Harvard Medical School. In addition, he is a key part of the Bill & Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery, the National Institutes of Health Martin Delaney HIV-1 Cure Collaboratory, and the Ragon Institute of MGH, MIT, and Harvard.

He received his Ph.D. in immunology from Oxford University and his M.D. summa cum laude from Harvard Medical School. 

Dr. Barouch’s laboratory focuses on studying the immunology and virology of HIV-1 infection and developing novel vaccine and cure strategies. He and his team have explored a series of novel vaccine technologies, and he is also working on strategies to address other global infectious diseases.

Dr. Barouch’s laboratory focuses on studying the immunology and virology of HIV-1 infection and developing novel vaccine and eradication strategies.  He has also applied his vaccine expertise to other infectious diseases such as Zika virus and tuberculosis.  He has advanced novel adenovirus vector-based HIV-1 vaccine candidates from concept and design to preclinical testing, ten phase 1/2a clinical trials, and a large phase 2b efficacy trial with the mosaic Ad26/Env vaccine in sub-Saharan Africa. He has also pioneered the use of broadly neutralizing antibodies for HIV-1 cure strategies, and a series of phase 1 clinical trials are currently underway. Dr. Barouch also led the world’s first demonstration of Zika vaccine protection in preclinical studies and has launched a series of phase 1 Zika vaccine clinical trials.

Dr. Barouch is board certified in internal medicine and infectious diseases, and he is committed to mentoring students, clinical fellows, research fellows, and junior faculty and to providing clinical care to patients with infectious diseases.